1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
TCI Co., Ltd.

TCI Co., Ltd.

TTPEX:8436
99.30
TWD
-0.50
(-0.50%)
10.94EPS
12.21P/E
12.67BMarket Cap
Nov 05Next Earn
TCI Co., Ltd.
TPEX:8436
(Taipei Exchange)

Recent

price

99.30

P/E

ratio

12.21

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
13.67
13.47
13.99
16.17
15.13
19.75
27.37
35.6
69.86
80.77
70.15
73.1
63.14
69.12
64.65
63.55
63.32
Revenue per Share
0.96
1.3
1.62
1.66
1.65
2.37
4.54
6.23
15.48
17.02
15.69
13.17
6.06
7.73
7.6
8.68
9.42
Basic EPS, GAAP
0.41
-2.49
2.25
-0.88
-1.86
1.4
3.88
3.82
20.06
-1.48
15.97
7.51
4.7
13.52
11.42
3.12
3.1
Free Cash Flow per Basic Share
0.13
0.06
0.08
0.12
0.46
0.53
0.86
1.32
2.03
6.06
8.88
8.87
8.92
5.1
7.36
10.7
- -
Dividend per Share
3.96
6.19
7.73
12.93
16.44
21.55
24.09
29.47
48.73
59.63
63.99
68.95
68.87
71.38
73.14
70.65
69.59
Book Value per Share
3.93
6.18
7.72
12.92
16.41
21.32
23.86
29.24
48.51
59.37
63.8
62.16
62.58
65.38
67.33
65.21
64.35
Tangible Book Value per Share
65
71
82
87
96
105
114
114
116
118
117
117
118
116
112
110
110
Basic Weighted Avg Shares
885
962
1,153
1,404
1,455
2,065
3,110
4,072
8,098
9,566
8,224
8,580
7,433
8,016
7,240
6,989
6,960
Sales/Revenue/Turnover
9.06
12.25
12.33
9.52
9.68
13
20.03
21.6
25.64
23.04
24.28
20.08
14.29
13.22
14.58
16.66
18.56
Operating Margin (%)
11
18
21
27
43
62
96
115
175
269
337
463
627
642
600
572
551
Depreciation Expense
62
93
134
144
158
247
516
712
1,795
2,016
1,839
1,546
713
896
851
955
1,036
Net Income, GAAP
22.51
27.06
12.9
15.68
21.21
16.58
19.13
19.05
18.09
15.27
15.72
19.58
36.36
15.55
14.17
9.75
11.33
Effective Tax Rate (%)
6.99
9.68
11.61
10.24
10.88
11.99
16.6
17.49
22.16
21.08
22.36
18.02
9.6
11.18
11.76
13.66
14.88
Profit Margin (%)
101
298
361
792
1,131
1,285
1,383
1,558
3,219
3,170
2,639
3,362
4,110
4,605
4,777
3,405
3,146
Working Capital
51
228
196
183
378
262
143
138
494
476
59
1,005
429
854
1,239
776
623
LT Debt
217
503
640
1,216
1,710
2,255
2,782
3,418
5,769
7,208
7,588
9,622
10,079
9,878
9,488
9,157
8,981
Total Equity
37.34
15.01
14.03
9.5
6.21
9.46
17.69
20.95
31.76
24.9
19.1
12.5
5.1
7.15
7.52
8.71
10.6
Return on Invested Capital (%)
38.57
16.6
15.75
12.61
9.23
11.08
18.71
21.4
35.4
27.65
21.46
14.03
5.13
7.08
6.78
7.19
8.77
Return on Capital (%)
57.94
25.97
23.45
15.51
10.84
12.54
20.65
23.17
39.41
31.36
25.13
19.8
8.8
10.98
10.44
12.03
14.32
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,370
1,857
1,676
LT Borrowings
678
594
518
LT Finance Leases
98
97
105
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
110
110
110
Market Capitalization
12,175
13,828
12,671

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
8,162
7,793
7,657
Cash, Cash Equivalents & STI
5,893
5,704
5,638
Accounts Receivable, Net
994
974
919
Inventories
736
724
795
Total Current Liabilities
4,758
4,076
4,511
Payables & Accruals
- -
- -
- -
ST Debt
2,370
1,857
1,676
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.73%
4.42%
-3.49%
Free Cash Flow
-63.99%
0.32%
-73.19%
Net Income, GAAP
26.51%
-7.4%
12.15%
Sales/Revenue/Turnover
17.02%
-2.87%
-3.47%
Total Cash Common Dividend
47.59%
7.89%
42.86%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,512
1,977
1,805
1,946
7,240
2025
1,587
1,796
1,740
1,866
6,989
2026
1,641
1,713
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.1
2.43
1.47
2.62
7.6
2025
1.24
2.16
2.5
2.78
8.68
2026
1.92
2.22
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
7.36
2025
- -
- -
- -
- -
10.7
2026
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
TCI Co., Ltd. (8436.TWO) operates as a contract development and manufacturing organization (CDMO) specializing in the research, development, production, and sale of functional health foods, dietary supplements, and skincare products. The company provides end-to-end services including market analysis, concept design, proprietary raw material development via Integrated Bioscience Design (IBD), formulation R&D, stability and safety testing, pilot production, and full-scale manufacturing for formats such as capsules, softgels, liquids, powders, functional beverages, snacks (jelly, bars, chocolates, gummies), facial/body/eye/lip masks, essences, sprays, creams, and gels; it also offers turnkey private-label solutions, wholesale chemical production, biotechnology R&D, and medical machinery sales. TCI serves nutraceutical and cosmetic sectors for domestic and international brands, with products distributed in Taiwan, Mainland China, the United States, North America, Europe, Asia, and over 67 countries globally. Founded in 1980 and headquartered at 8F, No. 187 Kang Chien Road, Taipei, Taiwan, TCI employs 1,120 people worldwide and maintains operations in the biotechnology and medical care industry as a TPEx-listed entity. The company targets brand owners seeking OEM/ODM services in wellness and beauty, leveraging a probiotics database of over 7,272 strains, 2,676+ patents/trademarks, and 362+ awards to deliver clinically backed, consumer-inspired innovations. In recent developments, TCI reports consolidated 2024 revenue of NT$7.24 billion, gross profit of NT$3.18 billion (44% margin), operating profit of NT$1.03 billion, and net profit of NT$974 million (EPS NT$7.60), with a proposed NT$10 per share dividend and cash reserves of NT$4.77 billion; it advances global expansion in North America, Europe, China, and Asia alongside AI-enhanced production, a new Medical Consultation Panel, and ESG initiatives including RE100 membership and 562,000 kg CO2 reduction. The company showcases liquid supplement expertise at SupplySide Global 2025, emphasizing clinically proven weight management innovations. Earlier, TCI completed a 18.4% stake acquisition in Maxigen Biotech Inc. for NT$370 million in 2021, bolstering its biotech capabilities.